ArticleScientific reports2025
Comprehensive analysis of the PLXNA3 gene on prognosis and immune characteristics in breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
PLXNA3 is a transmembrane protein essential for axon guidance and synapse formation, gaining attention in cancer research for its roles in cell migration, invasion, and signal transduction. However, its biological significance in breast cancer remains underexplored. Here, bulk RNA sequencing and survival analysis revealed that elevated PLXNA3 levels were correlated with increased malignancy and poorer survival in breast cancer. Single-cell RNA sequencing demonstrated that PLXNA3 was predominantly enriched in tumor cell clusters within the tumor immune microenvironment, rather than in immune cell clusters. In vitro experiments further demonstrated that knockdown and overexpression of PLXNA3 significantly altered the proliferative, invasive, and migratory capacities of breast cancer cells. Additionally, the overexpression of PLXNA3 was negatively correlated with immune activation status and served as a predictor of poor response to anti-PD1 immunotherapy. Our findings suggested that high expression of PLXNA3 is associated with poor prognosis in breast cancer and plays a crucial role in cancer immunity, making it a promising novel target for intervention in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.